Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics and Clinical Strategies

Read full text Summarise with VIRAT
Authors: Arun Kamireddy, Clifford R. Weiss, Jeff Martini, Michael Kelly, Maria Gnarra
Cited by: 0
References: 43

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective(s): To review the classification, genetics, diagnosis, and management of lymphatic malformations (LMs), emphasizing the clinical and therapeutic differences between macrocystic and microcystic subtypes to guide targeted treatment and subtype-specific clinical trial design. Methods: Narrative review synthesizing current literature on LM epidemiology, pathophysiology, imaging, histopathology, and treatments, including sclerotherapy, surgery, laser therapy, and targeted agents. Results: LMs are driven mainly by postzygotic PIK3CA mutations activating the phosphoinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway. Macrocystic LMs (>2 cm cysts) present as compressible masses, respond well to sclerotherapy, and allow radiologic volume assessment. Microcystic LMs (

Fields of Study & Subjects

Vascular Malformations and Hemangiomas Lymphatic System and Diseases Lymphatic Disorders and Treatments

Publication details

Journal / source
Journal of Vascular Anomalies
Volume
7
Issue
2
Pages
e133–e133
Publication date
24 March 2026
Language
EN